Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Conference Reports for NATAP

The Liver Meeting
AASLD 2024
Nov 15-19,
San Diego, CA


Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

	AASLD Nov 15-19 San Diego < Mazen Noureddin, MD, MHSc1; Mary Rinella, MD, FAASLD2; Rebecca Taub, MD3; Dominic Labriola, PhD3; Naim Alkhouri, MD, FAASLD4; Meena B. Bansal, MD, FAASLD5 1Houston Methodist Hospital, Houston, TX; 2The University of Chicago, Chicago, IL; 3Madrigal Pharmaceuticals, Conshohocken, PA; 4Arizona Liver Health, Phoenix, AZ; 5Icahn School of Medicine at Mount Sinai, New York, NY